LAST CHANCE: REGISTER BY MAY 20 TO SAVE UP TO $300
- 00Days
- 00Hrs
- 00Mins
- 00Secs
June 14-16, 2022
Delivered as a Hybrid EventIntercontinental Mark Hopkins Hotel, San Francisco, Californiakeyboard_arrow_right
Search & Filter keyboard_arrow_right
keyboard_arrow_left Hide
Day 2 - PST/PDT (Pacific Daylight, GMT-7)
keyboard_arrow_leftSearch & Filter
search
Streams
Formats
Day 2 - PST/PDT (Pacific Daylight, GMT-7)
search
Streams
Formats
8:00am - 9:00am60 mins
CONFERENCE DAY TWO - June 15th
Registration & Breakfast
9:00am - 9:15am15 mins
CONFERENCE DAY TWO - June 15th
Chairperson’s Opening Remarks
9:15am - 9:45am30 mins
CONFERENCE DAY TWO - June 15th
Integrated Target Discovery & TCR Generation Pipelines for TCR-Modified Cell Therapies
- Reagan Jarvis - CEO, Scientific founder, Anocca AB, Sweden
9:45am - 10:15am30 mins
CONFERENCE DAY TWO - June 15th
Identification of Novel pHLA Targets for Solid Tumor Targeting with High Potency Modalities
- Leah Sibener - Head of Therapeutic Discovery, Co-Founder, 3T Biosciences, USA
10:15am - 10:45am30 mins
CONFERENCE DAY TWO - June 15th
T Cell Engineering for Improved Safety & Efficacy
- Laurent Poirot - SVP Immunology, Cellectis, France
10:45am - 11:30am45 mins
CONFERENCE DAY TWO - June 15th
Refreshment Break in the Exhibit & Poster Hall
11:30am - 12:00pm30 mins
CONFERENCE DAY TWO - June 15th
CERo Therapeutics Case Study - Multifunctional CER T cells for Hematologic and Solid Tumors
- John Rossi - Head of Translational Research, CERo Therapeutics, USA
12:00pm - 12:30pm30 mins
CONFERENCE DAY TWO - June 15th
BOXR: A Platform for Improving T cell Performance in the Solid Tumor Microenvironment
- Amy Jensen Smith - Senior Director, Head of Discovery, SOTIO Biotech Inc., USA
12:30pm - 1:00pm30 mins
CONFERENCE DAY TWO - June 15th
Triumvira Case Study – TAC Technology and Promise in Solid Tumours
- Deyaa Adib - Chief Medical Officer, Triumvira Immunologics, Inc, USA
1:00pm - 1:30pm30 mins
CONFERENCE DAY TWO - June 15th
Improving T-Cell Function with Epigenetic & Genetic Reprogramming to Improve Cell Therapy Outcomes in Solid Tumours
- Tina Albertson - CMO and Head of Development, Lyell Immunopharma, USA
1:30pm - 2:40pm70 mins
CONFERENCE DAY TWO - June 15th
Networking Luncheon in the Exhibit & Poster Hall
2:40pm - 2:45pm5 mins
CONFERENCE DAY TWO - June 15th
Chairperson's Opening Remarks
- Leah Sibener - Head of Therapeutic Discovery, Co-Founder, 3T Biosciences, USA
2:45pm - 3:15pm30 mins
CONFERENCE DAY TWO - June 15th
Promising Safety and Efficacy Profile of a Novel Anti-CD20/CD19 Bi-Specific CAR-T (C-CAR039) Cell Therapy in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
- Yihong Yao - Lead Immuno Oncology Clinical Development, Translational Medicine and Oncology R&D, Cellular Biomedicine Group, USA & China
3:15pm - 3:45pm30 mins
CONFERENCE DAY TWO - June 15th
Translational Medicine data around ZUMA-7 (2nd Line LBCL of Axi-cel Vs SOC) – Association Between Biomarkers & Clinical Outcome
- Rhine Shen - Senior Director, Translational Medicine, Kite Pharma, USA
3:45pm - 4:15pm30 mins
CONFERENCE DAY TWO - June 15th
Spotlight Presentation - SmartLabs
4:15pm - 4:45pm30 mins
CONFERENCE DAY TWO - June 15th
Final Refreshment Break in the Exhibition Hall
4:45pm - 5:15pm30 mins
CONFERENCE DAY TWO - June 15th
TIL Case Study
- Parameswaran Hari, MD - Senior Vice President of Clinical Science, Iovance Biotherapeutics, Inc., USA
5:15pm - 5:45pm30 mins
CONFERENCE DAY TWO - June 15th
Maintaining Both Innate Killing & Specific Targeting of Heterogeneous Tumours with Chemotherapy-Resistant Chlorotoxin CAR-T Cells
- Kate Rochlin - Chief Operating Officer, IN8bio, USA
5:45pm - 6:45pm60 mins
CONFERENCE DAY TWO - June 15th
Cocktail Networking Reception in Exhibit & Poster Hall
Get the latest news.
As it happens
Sign up to get the latest on the agenda and speakers.
Filter
Streams
Formats